X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AUROBINDO PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AUROBINDO PHARMA GSK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 67.4 14.8 455.9% View Chart
P/BV x 11.8 3.8 309.6% View Chart
Dividend Yield % 1.1 0.4 262.0%  

Financials

 GSK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
AUROBINDO PHARMA
Mar-17
GSK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,838895 428.8%   
Low Rs2,637622 424.0%   
Sales per share (Unadj.) Rs354.2254.6 139.1%  
Earnings per share (Unadj.) Rs39.839.3 101.2%  
Cash flow per share (Unadj.) Rs42.946.6 92.0%  
Dividends per share (Unadj.) Rs30.002.50 1,200.0%  
Dividend yield (eoy) %0.90.3 281.1%  
Book value per share (Unadj.) Rs236.9160.0 148.1%  
Shares outstanding (eoy) m84.70585.88 14.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x9.13.0 306.8%   
Avg P/E ratio x81.419.3 421.6%  
P/CF ratio (eoy) x75.516.3 463.7%  
Price / Book Value ratio x13.74.7 288.2%  
Dividend payout %75.46.4 1,185.3%   
Avg Mkt Cap Rs m274,216444,390 61.7%   
No. of employees `0004.714.0 33.6%   
Total wages/salary Rs m4,83017,678 27.3%   
Avg. sales/employee Rs Th6,387.010,667.8 59.9%   
Avg. wages/employee Rs Th1,028.31,264.3 81.3%   
Avg. net profit/employee Rs Th717.11,645.8 43.6%   
INCOME DATA
Net Sales Rs m30,000149,157 20.1%  
Other income Rs m7281,159 62.8%   
Total revenues Rs m30,728150,316 20.4%   
Gross profit Rs m4,19034,343 12.2%  
Depreciation Rs m2634,276 6.2%   
Interest Rs m0667 0.0%   
Profit before tax Rs m4,65530,558 15.2%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7447,597 23.0%   
Profit after tax Rs m3,36823,012 14.6%  
Gross profit margin %14.023.0 60.7%  
Effective tax rate %37.524.9 150.7%   
Net profit margin %11.215.4 72.8%  
BALANCE SHEET DATA
Current assets Rs m16,74292,062 18.2%   
Current liabilities Rs m7,20266,223 10.9%   
Net working cap to sales %31.817.3 183.6%  
Current ratio x2.31.4 167.2%  
Inventory Days Days52106 48.9%  
Debtors Days Days2168 30.7%  
Net fixed assets Rs m8,63562,919 13.7%   
Share capital Rs m847586 144.6%   
"Free" reserves Rs m19,22293,133 20.6%   
Net worth Rs m20,06993,719 21.4%   
Long term debt Rs m101,814 0.6%   
Total assets Rs m30,038162,494 18.5%  
Interest coverage xNM46.8-  
Debt to equity ratio x00 2.6%  
Sales to assets ratio x1.00.9 108.8%   
Return on assets %11.214.6 76.9%  
Return on equity %16.824.6 68.3%  
Return on capital %25.532.7 77.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52875,838 0.7%   
Fx outflow Rs m7,19330,224 23.8%   
Net fx Rs m-6,66545,613 -14.6%   
CASH FLOW
From Operations Rs m2,36032,786 7.2%  
From Investments Rs m3,008-17,870 -16.8%  
From Financial Activity Rs m-5,108-19,153 26.7%  
Net Cashflow Rs m260-4,239 -6.1%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.0 128.3%  
FIIs % 23.8 27.7 85.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.2 151.0%  
Shareholders   102,036 69,601 146.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALEMBIC LTD  SUN PHARMA  AJANTA PHARMA  NOVARTIS  ALEMBIC PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS